Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | YAP1 | P46937 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961352 | 0.91 | HRH3 (0.46) | MAOBTACR1YAP1FFAR1MAPT | |
| SCHEMBL3958223 | 0.88 | MRGPRX4 (0.46) | S1PR1S1PR5MRGPRX4 | |
| SCHEMBL3952617 | 0.88 | YAP1 (0.49) | YAP1MAPT | |
| SCHEMBL3950413 | 0.86 | YAP1 (0.44) | YAP1MAPTHTT | |
| SCHEMBL3958108 | 0.85 | YAP1 (0.49) | YAP1MAPT | |
| SCHEMBL3957249 | 0.84 | MAOB (0.46) | MAOBTACR1YAP1 | |
| SCHEMBL3978974 | 0.83 | MAPT (0.47) | TACR1MAPTSLC6A2SLC6A4 | |
| SCHEMBL3960314 | 0.82 | YAP1 (0.45) | YAP1HTT | |
| SCHEMBL3960326 | 0.81 | KIT (0.42) | YAP1FFAR1 | |
| SCHEMBL3961349 | 0.81 | MAPT (0.41) | TACR1YAP1FFAR1S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550456-B2 | Substituted aryl cycloalkanoyl derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-7491723-B2 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2009-02-17 | — | — | US | disclosed |
| US-7419980-B2 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7402698-B2 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-26 | — | — | US | disclosed |
| US-7365076-B2 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1687288-B1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20050234058-A1 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-10-20 | — | — | US | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005037807-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037207-A2 | ARYLALKYL-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE INCLUDING VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037809-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037279-A1 | 1- 2’ (1, 4’-BIPERIDIN-1’-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | MAOB 12/4885NR4A2 2596/4885TACR1 194/4885 |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | MAOB 50/4885NR4A2 3308/4885TACR1 155/4885 |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | HTR3A, MAOA, GLS | MAOB 17/4885NR4A2 2408/4885TACR1 157/4885 |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | MAOB 20/4885NR4A2 3950/4885TACR1 221/4885 |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | MAOA, MAOB, SDHA | MAOB 2/4885NR4A2 2089/4885TACR1 382/4885 |
| US-20050234058-A1 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | ASNS, GLS, GYS1 | MAOB 54/4885NR4A2 4193/4885TACR1 177/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | MAOB 2/4885NR4A2 2089/4885TACR1 382/4885 |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | COMT, MAOA, HTR3A | MAOB 6/4885NR4A2 2002/4885TACR1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.